[
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d1540766363dfe367d9892098972e7ca0518be0a5b5f0ca1d6a2176ed9af31b3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760719920,
      "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "id": 137145783,
      "image": "",
      "related": "EW",
      "source": "MarketWatch",
      "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d1540766363dfe367d9892098972e7ca0518be0a5b5f0ca1d6a2176ed9af31b3"
    }
  },
  {
    "ts": null,
    "headline": "WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?",
    "summary": "West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.",
    "url": "https://finnhub.io/api/news?id=c001e10d4eea31da264ef2943e5bf960caa5891b21d467b525f4626e6794b85f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760706480,
      "headline": "WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?",
      "id": 137125895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.",
      "url": "https://finnhub.io/api/news?id=c001e10d4eea31da264ef2943e5bf960caa5891b21d467b525f4626e6794b85f"
    }
  },
  {
    "ts": null,
    "headline": "Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings",
    "summary": "Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.",
    "url": "https://finnhub.io/api/news?id=578f4b56cf5efa2d43d82a10e94cb49937ba231187e05539b06707b62f288fd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703960,
      "headline": "Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings",
      "id": 137126029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.",
      "url": "https://finnhub.io/api/news?id=578f4b56cf5efa2d43d82a10e94cb49937ba231187e05539b06707b62f288fd6"
    }
  }
]